GNPX Genprex, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1595248 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-233.7%
ROA-160.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets21.7%
Debt / equity0.00x
Current ratio4.26x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.74M | $2.68M | $2.75M | $2.20M | $2.19M | $2.50M | $2.54M | $2.84M |
| SG&A expense | $1.53M | $1.80M | $1.75M | $1.32M | $1.15M | $2.18M | $1.43M | $1.50M |
| Operating income | -$4.27M | -$4.48M | -$4.49M | -$3.52M | -$3.35M | -$4.68M | -$3.97M | -$4.34M |
| Net income | -$4.24M | -$4.45M | -$4.46M | -$3.79M | -$3.80M | -$4.67M | -$3.96M | -$4.33M |
| EBITDA | — | — | -$4.49M | -$3.52M | -$3.35M | -$4.68M | -$3.97M | -$4.34M |
| EPS (basic) | -5.30 | -9.40 | -0.64 | — | -109.39 | -185.30 | -12.98 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $15.35M | $15.15M | $18.05M | $7.83M | $1.10M | $1.35M | $3.47M | $1.60M |
| Current assets | $16.19M | $15.84M | $18.80M | $8.36M | $1.72M | $2.06M | $4.16M | $2.08M |
| PP&E, net | — | — | — | $0 | — | — | — | $0 |
| Intangibles | — | — | — | — | — | — | — | $0 |
| Total assets | $17.52M | $17.14M | $20.31M | $10.16M | $3.56M | $3.83M | $6.01M | $4.12M |
| Current liabilities | $3.80M | $2.34M | $3.35M | $2.17M | $2.55M | $2.44M | $2.14M | $2.50M |
| Total liabilities | $3.80M | $2.34M | $3.38M | $2.20M | $2.79M | $2.44M | $2.14M | $2.50M |
| Shareholders' equity | $13.72M | $14.80M | $16.93M | $7.96M | $767,808 | $1.39M | $3.87M | $1.62M |
| Shares outstanding | 1.22M | 506,218 | 9.04M | 149,811 | 1.00M | 33.15M | 24.15M | 217,234 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.94M | -$5.14M | -$3.14M | -$4.10M | -$3.19M | -$3.86M | -$4.16M | -$3.87M |
| Investing cash flow | — | — | — | $0 | $0 | $0 | $0 | -$1 |
| Financing cash flow | $3.13M | $2.24M | $13.36M | $10.83M | $2.94M | $1.74M | $6.03M | $3.98M |
| Depreciation & amortization | — | — | $0 | $0 | $0 | $0 | $0 | $463 |
| Stock-based compensation | $40,000 | $68,354 | $118,634 | -$363,243 | $20,000 | $458,918 | $184,773 | $265,034 |
Free plan shows the latest 8 periods; Pro shows all 41 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.